Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of mPnC Candidate (PF-07831695) in Toddlers
NCT06116591Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2023
- Primary completion
- May 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of RSVpreF vaccine in pneumococcal infection, sponsored by Pfizer. Started Nov 2023; status: completed.
02
Drugs
RSVpreF vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT06116591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06116591.